Adva-27a is an anti-cancer compound which has proven effective at killing multidrug resistant breast cancer cells (MCF-7/MDR) and small-cell lung cancer cells (H69AR).
Sunshine president and CEO Steve Slilaty said the company is working with Beta Pharma Canada which has good in-house synthesis capability and can amass additional resources through its corporate affiliations.
"We anticipate delivery of the new batch of Adva-27a together with the synthesis parameters by the end of the month," Slilaty added.
Beta Pharma Canada, an affiliate of Beta Pharma, is a Canadian small-molecule drug discovery and manufacturing company specializing in design, synthesis and process development of novel pharmaceutical compounds.